AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03746795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simultaneous measurement by spirometer and EIT
Description: Spirometric examinations will be realized using the simultaneous measurement by spirometer and EIT
Study NCT03359863 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Subjects will receive pirfenidone for 52 weeks, titrated to 2403 mg/day (3 capsules, 3× daily) after a 4-week titration period (1 capsule, 3x daily for 2 weeks, 2 capsules, 3x daily for 2 weeks) for a total of 56 weeks of pirfenidone. Eligible participants will continue pirfenidone beyond 56 weeks.
Study NCT01261663 — intervention group
Intervention type: OTHER
Intervention: oral nutritional energy and protein enriched supplement (NOS)
Study NCT01368380 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological intervention
Description: Couples in the intervention group attends six to eight couple-sessions performed by a psychologist.
Study NCT00919737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NPC-08
Description: Polifeprosan 20 with Carmustine 3.85%
Study NCT04467151 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-SARS-CoV-2 plasma
Description: Administration of anti-SARS-CoV-2 convalescent plasma
Study NCT04467151 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo (albumin 5%)
Study NCT02629393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORGN001 (formerly ALXN1101)
Study NCT04332549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PICS (Reconstitution Method 1 or 2)
Description: dose: 260mg/m2 Frequency: 2 period cross over study Route of administration : intravenous infusion duration of therapy: 2 cycles of PICS
Study NCT02466581 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Orencia
Description: Abatacept: 125 mg s.c. every week. Methotrexate: 25mg/week
Study NCT02236624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Study NCT02466581 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RoActemra
Description: Tocilizumab is given as 4-weekly infusions at dosage 8 mg/kg or 162 mg in solution s.c. every week. Methotrexate: 25mg/week
Study NCT01793922 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PD
Description: pneumodilation
Study NCT01793922 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: POEM
Description: peroral endoscopic myotomy
Study NCT03624036 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: brexucabtagene autoleucel
Description: CAR-transduced autologous T cells administered intravenously
Study NCT03624036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered intravenously
Study NCT03624036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered intravenously
Study NCT02708706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyaluronic acid (hyruan)
Description: 2cc hyaluronic acid
Study NCT02708706 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: patient received traditional physical therapy, including therapeutic exercise and stretch exercise
Study NCT02708706 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Description: patient received traditional physical therapy, including therapeutic exercise and stretch exercise
Study NCT02783859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic Acid
Study NCT02783859 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Amoxicillin-clavulanic Acid)
Study NCT01083472 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Strattice(TM) Reconstructive Tissue Matrix
Description: Strattice(TM) TM will be used to support the repair of abdominal wall defect
Study NCT01083472 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suture/suture with absorbable mesh
Description: Abdominal wall defect will be repaired with suture alone or absorbable mesh with suture
Study NCT02774278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib will be administered at 150 milligrams (mg) orally daily until disease progression, unacceptable toxicity or death.
Study NCT02122523 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Near-Infrared (NIR) dye Indocyanin Green (ICG)
Study NCT02122523 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Near-Infrared (NIR) dye Indocyanin Green (ICG)
Study NCT01312675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: S.A.F.E.BT
Description: Five (5) S.A.F.E.BT treatments within a 7 day treatment period.
Study NCT01538407 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Strength Training
Description: The exercises will be performed in standard strength training equipment. Prior to each of the strengthening exercise sessions, a warm up phase is performed by 5-10 minutes of ergometer cycling at a moderate intensity. Muscle strengthening exercises will be performed according to the standard progressive resistance and overload principle. The exercise programme consists of three exercises performed with three sets of 10 repetitions at 60%-85% of patient's 10RM. Training load will be progressed by means of bi-weekly estimates of muscle strength to ensure a constant load of 60%-85% RM. Exercises are: 1. Leg extension, 2. Leg press, and 3. Forward lunges.
Study NCT00827619 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Zilver® Flex™ Vascular Stent
Description: Stenting of the Above-the-Knee Femoropopliteal Artery
Study NCT01339013 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Anesthetic Conserving Device (AnaConDa )
Description: Standard HME was replaced by AnaConDa. AnaConDa has charcoal filter, HME does not.
Study NCT01872936 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Miravirsen
Study NCT01872936 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Telaprevir
Study NCT01872936 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ribavirin
Study NCT00491530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-335
Description: Oral coadministration of ABT-335 (135 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
Study NCT00491530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosuvastatin calcium
Description: Oral coadministration of rosuvastatin calcium (20 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
Study NCT00491530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: simvastatin
Description: Oral coadministration of simvastatin (40 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
Study NCT00491530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin calcium
Description: Oral coadministration of atorvastatin calcium (40 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
Study NCT01293669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-6987
Description: TC-6987-23 (TC-6987 HCl) as experimental treatment: 20 mg loading dose (2 capsules) on Day 1 and 10 mg (1 capsule) on Days 2 to 28 (dose expressed as free base). Each dose will be given once daily.
Study NCT01293669 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo: Mode of administration: p.o. (microcrystalline cellulose in capsule) given once daily.
Study NCT02741531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bladder filled with saline solution
Description: Patients in this arm will have their bladders filled with 150 cc of saline solution.
Study NCT02741531 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: saline solution
Description: Saline solution will be used to partially fill patients' bladders
Study NCT04268212 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bitter melon juice (100 ml)
Description: Fresh bitter melon fruits were purchased from certified local groceries. The seeds of bitter melon were removed, and the juice was obtained from the raw fruit using a blender. Every 140 g of bitter melon fruit produced approximately 100 ml bitter melon juice.
Study NCT04268212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The walking exercise was started 15 minutes after the glucose load. Walking speed was determined to elicit 65% of the maximum heart rate (HRmax) during exercise for each participant. HRmax was estimated using the America College of Cardiology prediction model, HRmax=208 - 0.7 × age. All participants wore a heart rate monitor (Polar, Vantage, XL) around the chest to assess exercise intensity. A rate of perceived exertion was assessed every 2 minutes based on the Borg's scale.
Study NCT03072875 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAMS-RAS
Study NCT05581888 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: trifocal intraocular lens
Description: Binocular implantation of two different trifocal intraocular lens in high myopic cataracts
Study NCT01366105 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V.A.C. by K.C.I.
Description: Negative Pressure Wound Therapy, Delivered by Vacuum Assisted Closure (KCI) across closed surgical incision at completion of surgery
Study NCT00182637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Study NCT01023464 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: FID114657
Description: artificial tears
Study NCT01023464 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: SootheXP Emollient (Lubricant) Eye Drops
Description: artificial tears
Study NCT02767245 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thiamine
Description: Thiamine IV 100 mg/day
Study NCT03889795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin oral pill will be taken daily at breakfast (cohort 1) and breakfast and dinner (cohort 2 and 3).
Study NCT03889795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin oral pill will be taken daily in the evening.
Study NCT03889795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Digoxin oral pill will be taken once daily.
Study NCT03024632 — intervention group
Intervention type: PROCEDURE
Intervention: Trial of labor
Description: trial of labor after 3 or more previous cesarean deliveries
Study NCT03052153 — intervention group
Intervention type: OTHER
Intervention: No investigational intervention performed for this study
Description: No investigational intervention for the purpose of this study was performed; data collected is retrospective data previously collected for non-research purposes.
Study NCT00754286 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aromatherapy Scented Wand
Description: The aromatherapy used in this will be Quease Ease™, manufactured by Soothing Scents, Inc. Quease Ease is a blend of lavender, spearmint, ginger, and peppermint soaked into a pad placed within a wand dispenser that emits a fragrance when placed within a few inches of the nares. Participants will be given aromatherapy wand at the onset of their chemotherapy treatment. Participants will be instructed how to self-administer the aromatherapy treatment. Specifically, they can hold the wand under their nose and breathe in deeply five times when they feel symptoms of nausea or anxiety.
Study NCT00754286 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo wand
Description: Placebo wands will look identical to the scented wands but will not contain a scent. Participants will be given the placebo wand at the onset of their chemotherapy treatment. Participants will be instructed how to self-administer the placebo treatment. Specifically, they can hold the wand under their nose and breathe in deeply five times when they feel symptoms of nausea or anxiety.
Study NCT02474901 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Live Attenuated Influenza Vaccine
Study NCT01496703 — intervention group
Intervention type: OTHER
Intervention: no intervention, this is an observational retrospective trial
Description: no intervention, this is an observational retrospective trial
Study NCT04102982 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Camrelizumab
Description: Patients will be treated with camrelizumab alone.
Study NCT04102982 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Camrelizumab plus microwave ablation
Description: In the group, microwave ablation will be administrated to the primary tumors, followed by camrelizumab.
Study NCT03169972 — intervention group
Intervention type: BIOLOGICAL
Intervention: ADYNOVATE
Description: Antihemophilic Factor (Recombinant), PEGylated
Study NCT04612127 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement consumption and physical exercise
Description: The consumption time of the experimental product was 90 days and the control consumption time was 90 days.~During this time, training should be done three times a week.
Study NCT04612127 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary supplement consumption and physical exercise
Description: The consumption time of the experimental product was 90 days and the control consumption time was 90 days.~During this time, training should be done three times a week.
Study NCT03708770 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: everlinQ endoAVF System
Study NCT03517007 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opt-Out Protocol
Description: Should an eligible patient pass the safety screen and be randomized to the intervention arm of the trial, the designated pharmacist will approach the patient's primary provider in charge of antibiotic decision-making The pharmacist will inform the provider the patient's antibiotics can be de-escalated unless the provider opts out.
Study NCT02856373 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: RNS and RDN
Description: The patients will undergo electrical renal nerve stimulation and subsequently renal nerve denervation
Study NCT01184118 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FP 220 mcg 2 puffs BID
Description: The design is a prospective 16-week open-label study of inhaled FP hydrofluoroalkane-propelled metered dose inhaler (HFA-MDI), 220 mcg, 4 puffs BID in 36 ICS naive asthma subjects. This is followed by a 4-week run-out period, including FP 220 mcg 2 puffs BID for 2 weeks, then either continue FP 220 mcg 2 puffs BID or discontinue FP (as tolerated), for the remaining two weeks, with subsequent transition to clinical care.
Study NCT04147741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Pre-Workout Supplement
Description: One week familiarisation, one-week training, two weeks washout period and one-week training.~15 Minutes before every training, the Pre-Workout Arm (PRE-W) will take a Supplement shake, consisting of some ingredients (Multi-Ingredient, explained before) and the Placebo Comparator Arm (CHO) will drink a Placebo shake, consisting of Maltodextrin.
Study NCT04147741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pre-Workout Supplement
Description: One week familiarisation, one-week training, two weeks washout period and one-week training.~15 Minutes before every training, the Pre-Workout Arm (PRE-W) will take a Supplement shake, consisting of some ingredients (Multi-Ingredient, explained before) and the Placebo Comparator Arm (CHO) will drink a Placebo shake, consisting of Maltodextrin.
Study NCT04147741 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Resistance Training
Description: -Resistance Training days (Monday-Wednesday-Friday): Before training starts, Tensiomyography and Energy Feeling will be assessed (Energy Level, Fatigue Level, Feeling of Alertness, and Feeling of Focus on the task). Immediately after finishing, Tensiomyography and Performance (Vertical Jump, Overhead Medicine Ball Throw, and Maximal Mid-Tigh Pull Isometric Strength) will be assessed. Training Protocol: 10 minutes of standardized warm-up, Strength Circuit training using free weights (Parallel Squat; Bench Press; Alternate Box Set-Ups; Shoulder Press; Alternate Lunges; Up-right Row; Hip-Thrust; Squat on Isoinertial Fly-Wheel or Drop Jump). The participants will have to perform 16 repetitions of each exercise, with 30 seconds rest and 3 minutes rest after every set. If they can complete 16 repetitions easily, 2,5 to 5 kg will be added for the next set. Also, whole-body Perceptual Response will be assessed using the 0-10 OMNI-RES Scale, after every set and 15 minutes after finishing.
Study NCT04147741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: -Resistance Training days (Monday-Wednesday-Friday): Before training starts, Tensiomyography and Energy Feeling will be assessed (Energy Level, Fatigue Level, Feeling of Alertness, and Feeling of Focus on the task). Immediately after finishing, Tensiomyography and Performance (Vertical Jump, Overhead Medicine Ball Throw, and Maximal Mid-Tigh Pull Isometric Strength) will be assessed. Training Protocol: 10 minutes of standardized warm-up, Strength Circuit training using free weights (Parallel Squat; Bench Press; Alternate Box Set-Ups; Shoulder Press; Alternate Lunges; Up-right Row; Hip-Thrust; Squat on Isoinertial Fly-Wheel or Drop Jump). The participants will have to perform 16 repetitions of each exercise, with 30 seconds rest and 3 minutes rest after every set. If they can complete 16 repetitions easily, 2,5 to 5 kg will be added for the next set. Also, whole-body Perceptual Response will be assessed using the 0-10 OMNI-RES Scale, after every set and 15 minutes after finishing.
Study NCT04147741 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Endurance Training
Description: - Endurance Training days (Tuesday-Thursday): Energy Feeling Questionnaire will be implemented before training. The training will consist of 30 minutes cycling at their Fatmax Intensity (\~60% Vo2max) on a Cycloergometer (estimated during familiarisation week). Also, the Heart Rate will be recorded during the whole training. Besides, Perception of Effort will be assessed using the 6-20 version of the Borg Scale every 5 minutes during training and 15 minutes after it has been completed.
Study NCT04147741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Endurance Training
Description: - Endurance Training days (Tuesday-Thursday): Energy Feeling Questionnaire will be implemented before training. The training will consist of 30 minutes cycling at their Fatmax Intensity (\~60% Vo2max) on a Cycloergometer (estimated during familiarisation week). Also, the Heart Rate will be recorded during the whole training. Besides, Perception of Effort will be assessed using the 6-20 version of the Borg Scale every 5 minutes during training and 15 minutes after it has been completed.
Study NCT01374464 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene brachial plexus block
Description: 4 different administrations of levobupivicaine will be applied:~1. High Volume, High Concentration = 15mls of 0.75% levobupivicaine~2. High Volume, Low Concentration = 15mls of 0.5% levobupivicaine~3. Low Volume, High Concentration = 5mls of 0.75% levobupivicaine~4. Low Volume, Low Concentration = 5mls of 0.5% levobupivicaine
Study NCT00800384 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable defibrillator
Description: Implantable defibrillator to detect and terminate ventricular arrhythmias
Study NCT00800384 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implantable defibrillator
Description: Implantable defibrillator to detect and terminate ventricular arrhythmias
Study NCT01351558 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Knee muscle strengthening exercises
Description: Muscle strengthening exercises of the quadriceps and hamstring muscles will be performed based on a standard muscle strengthening exercise paradigm: 3 sets with 6-8 repetitions (corresponding to approximately 80% repetition maximum (RM)) will be performed. The training load will be progressed by means of weekly estimates of muscle strength to ensure a constant load of 80% RM. The exercises will be supervised
Study NCT01351558 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Upper extremity strengthening exercises
Description: Muscle strengthening exercises of the upper amrs and shoulder girdle will be performed based on a standard muscle strengthening exercise paradigm: 3 sets with 6-8 repetitions (corresponding to approximately 80% repetition maximum (RM)) will be performed. The training load will be progressed by means of weekly estimates of muscle strength to ensure a constant load of 80% RM. The exercises will be supervised
Study NCT01351558 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardiovascular fitness exercises
Description: Cardiovascular fitness exercises encompass circuit training including exercises on (but not limited to): ergometer cycles, treadmills (running), and cross-trainers. The exercise intensity is aiming at exercises within 60-85% of maximum heart rate (defined as 220 - age). The heart rate is monitored using a standard heart rate monitor. The exercises will be supervised
Study NCT03321032 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polymer-free amphilimus-eluting stents
Description: Cre8 Evo coronary stent system (CID, Saluggia, Italy)